Nifedipine (BAY-a-1040)

Licensed by Pfizer Catalog No.S1808

For research use only.

Nifedipine (BAY-a-1040) is a dihydropyridine calcium channel blocker, used to lower hypertension and to treat angina.

Nifedipine (BAY-a-1040) Chemical Structure

CAS No. 21829-25-4

Selleck's Nifedipine (BAY-a-1040) has been cited by 11 Publications

2 Customer Reviews

Purity & Quality Control

Choose Selective Calcium Channel Inhibitors

Other Calcium Channel Products

Biological Activity

Description Nifedipine (BAY-a-1040) is a dihydropyridine calcium channel blocker, used to lower hypertension and to treat angina.
Targets
calcium channel [1]
In vitro

Nifedipine causes a significant concentration-dependent increase in eNOS protein expression by cultured human coronary artery endothelial cells. [1] Nifedipine antagonizes L-type Ca+ channels found throughout the cardiovascular system, but also blocks Kv channels, which are members of the same supergene family. [2] Nifedipine dose-dependently decreases the values of [(3)H]-thymidine incorporation and total cellular protein content as well as the levels of phosphorylated extracellular signal-regulated protein kinase (ERK) 1/2, mitogen-activated protein kinase kinase (MEK) 1/2, and even the phosphorylation of Pyk2, in vascular smooth muscle cells (VSMC). Nifedipine suppresses the levels of proliferative cell nuclear antigen (PCNA) dose-dependently in both VSMC and balloon-injured thoracic aortae in VSMC. [3]

In vivo Nifedipine (3 mg/kg) slightly lowers the level of systolic and/or diastolic blood pressure or increased the heart rate in rats. [3] Nifedipine (1 μm) produces a maximal inhibition of the store-operated pathway in choroidal arteriolar smooth muscle. [4] Nifedipine (20 and 40 mg/kg) markedly prevents the HCl plus ethanol-induced gastric mucosal injury and the increase in the content of thiobarbituric acid-reactive substances in the injured mucosa in rats. Nifedipine (20 and 40 mg/kg) dose-dependently promotes the ulcer healing and inhibites the increase in the content of thiobarbituric acid-reactive substances in the ulcerated mucosa in rats. [5]

Protocol (from reference)

Solubility (25°C)

In vitro

DMSO 69 mg/mL
(199.23 mM)
Water Insoluble
Ethanol ''15 mg/mL

Chemical Information

Molecular Weight 346.33
Formula

C17H18N2O6

CAS No. 21829-25-4
Storage 2 years 4°C(in the dark) powder
1 week 4°C(in the dark) in solvent
Smiles CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05096728 Recruiting Drug: Nifedipine XL Preeclampsia With Severe Features Ohio State University December 1 2021 --
NCT04392375 Recruiting Drug: Nifedipine 30 MG|Drug: Placebos Preeclampsia Severe Ohio State University June 9 2020 Phase 4
NCT03695107 Unknown status Drug: Nifedipine controlled released tablets Chronic Kidney Diseases The Third Xiangya Hospital of Central South University October 2 2019 --
NCT02902354 Withdrawn Other: Nifedipine for tocolysis Tocolysis With Nifedipine St. Louis University September 2016 Not Applicable
NCT03710395 Unknown status Procedure: Blood and breast milk sampling|Drug: Nifedipine Drug Transporter Natalia Valadares de Moraes|Hospital das Clínicas de Ribeirão Preto|Universidade Estadual Paulista Júlio de Mesquita Filho December 14 2015 Phase 4

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Nifedipine (BAY-a-1040) | Nifedipine (BAY-a-1040) supplier | purchase Nifedipine (BAY-a-1040) | Nifedipine (BAY-a-1040) cost | Nifedipine (BAY-a-1040) manufacturer | order Nifedipine (BAY-a-1040) | Nifedipine (BAY-a-1040) distributor